Paper
Aliskiren/Hydrochlorothiazide Combination
Published 2012 · Claudine M. Baldwin, Greg L. Plosker
Drugs
5
Citations
0
Influential Citations
Abstract
Abstract▲ Aliskiren/hydrochlorothiazide is a single-pill combination of the first in the new class of non-peptide direct renin inhibitors (aliskiren) and a thiazide diuretic (hydrochlorothiazide [HCTZ]) that achieves blood pressure (BP) reductions greater than those seen with either component alone.▲ In double-blind, 8-week clinical trials, aliskiren and HCTZ (as a combination of the individual components or as single-pill combinations) reduced mean sitting systolic and diastolic BP from baseline to a significantly greater extent than placebo, aliskiren monotherapy and HCTZ monotherapy. Aliskiren/HCTZ produced additional BP reductions in patients inadequately responsive to 4 weeks’ prior treatment with aliskiren or HCTZ alone.▲ Responder rates and BP control rates further demonstrated the benefits of aliskiren/HCTZ combination therapy over monotherapy with individual components in patients with mild to moderate hypertension.▲ Aliskiren plus HCTZ appeared to be effective as long-term (up to 1 year) combination treatment in an open-label trial.▲ In a 12-week placebo-controlled trial in obese patients with hypertension, BP reductions and responder and control rates were significantly greater with aliskiren/HCTZ than with HCTZ alone.▲ Aliskiren/HCTZ was generally well tolerated in clinical trials, with most adverse events being mild and transient in nature.
RCTThe combination of aliskiren and hydrochlorothiazide effectively reduces blood pressure and improves response and control rates in patients with mild to moderate hypertension.
Full text analysis coming soon...